Mintz | Attorneys | Corporate Litigation

BioPharma Named Defendant in Medicaid Overpayment Case

Mintz secured a full release of a biopharmaceutical company in a Louisiana state court case over alleged inflated drug price reporting. The client agreed to a nuisance value settlement of the case, resolving claims its actions cost the state’s Medicaid program more than $20 million.

Learn More

Nov

2018

Food and Drug Law Journal 2018 Symposium

Washington, DC

Energy XXI Bankruptcy Holders Receive Cash Payout

Mintz represented Wilmington Savings Fund Society, FSB, the indenture trustee for holders of $367 million in notes, in oil and gas developer Energy XXI, Inc.’s contentious Texas bankruptcy. The noteholders ultimately received a cash payout of more than double the original offer amount.

Learn More

Nov

2018

2018 Boston Navigate Investor Corporate Customer Connect

Federal Reserve Bank of Boston, 600 Atlantic Ave., Boston, MA 02210

Digital Health Company Seeks Guidance in Navigating FDA Policy

Mintz helped a digital health company develop corrective actions following a manufacturing inspection related to its Class 1 medical device. After the FDA deemed the company’s health tracking mobile application a regulated device, Mintz submitted an advocacy position paper to the agency.

Learn More

Nov

2018

The 9th Annual Advertising and Promotion of Medical Devices Conference

The Madison Hotel, Washington, D.C.

Protecting Cutting-Edge Tech for Hyundai & Kia

Mintz annually handles hundreds of patents for Hyundai/Kia, which uses Mintz as one of its key US patent counsel. Patent analyst and investment organization Ocean Tomo ranked Mintz's practice among the top 20 US firms for patent quality, based in part on Mintz's work for Hyundai/Kia.

Learn More

Nov

2018